Skip to Content

BCAL Diagnostics Ltd Ordinary Shares BDX Stock Quote

| Rating as of


Morningstar‘s Stock Analysis BDX

Currency in AUD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics BDX

Company Profile BDX

Business Description

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.

50 Clarence Street, Suite 506, Level 5
Sydney, NSW, 2000, Australia
T +61 290787671
Industry Diagnostics & Research
Most Recent Earnings
Fiscal Year End Jun 30, 2021